scholarly journals Subcutaneous panniculitis-like T-Cell lymphoma: A mixed diagnostic approach to diagnosing a vague clinical picture

2019 ◽  
Vol 3 (2) ◽  
pp. 90-97
Author(s):  
Callie Roberts Hill ◽  
Apphia Wang ◽  
Boni E. Elewski ◽  
Peter G Pavlidakey

Subcutaneous panniculitis-like T-Cell lymphoma (SPTCL) is a rare subtype of cutaneous T-cell lymphoma, and it has been associated with a range of clinical symptoms from mild to severe. Most commonly, this disease is described as following a slowly progressing course, associated with vague constitutional symptoms and good prognosis. This case report describes the clinical presentation and findings of SPTCL in a 31 year old female and describes the challenges of recognizing and properly diagnosing this disease. SPTCL has been described as a mimicker of other, more common and nonmalignant diseases of the skin, such as lupus panniculitis. This report highlights a variety of specific tests including immunohistochemical and immunoperoxidase staining, as well as genotypic analysis of T-cell receptors, that were effective in combination in isolating this diagnosis. Moreover, choice of treatment for these patients can be challenging, as an array of interventions have been described in past cases to treat SPTCL. This report recognizes the efficacy of a treatment course that included a six-cycle course of combined chemotherapy (vincristine, doxurubicine, cyclophosphamide, and prednisone, also known as CHOP) followed by weekly methotrexate and PET scan surveillance for two years. With both initial and maintenance therapy, this patient showed excellence response evidenced by a progressive decrease in metabolic activity of malignant lesions, lack of new lesions, and remaining without symptoms. While this disease is rare, it is important to include SPTCL in the differential when considering patients with a panniculitic picture.

2021 ◽  
Vol 14 (9) ◽  
pp. e243490
Author(s):  
Lakshmi Shree Kulumani Mahadevan ◽  
Metin Ozdemirli

Subcutaneous panniculitis-like T cell lymphoma (SPTCL) is a rare cutaneous T cell malignancy of cytotoxic T cell origin. It is frequently associated with autoimmune diseases. It is known to preferentially involve subcutaneous adipose tissue and histologically resembles lupus panniculitis. The aetiology and risk factors of SPTCL are unclear and there are limited studies available since this entity was initially described in 2001. There are even fewer case reports describing the association between SPTCL and chronic lymphocytic leukemia (CLL). In this article, we present a case of SPTCL arising during treatment for CLL. We conducted an extensive review of literature to delve into the possible risk factors for SPTCL development in association with CLL, including pre-existing haematological malignancies, autoimmune conditions, immunomodulation and immunosuppressive chemotherapy.


2015 ◽  
Vol 39 (2) ◽  
pp. 206-211 ◽  
Author(s):  
Francesca Bosisio ◽  
Sebastiana Boi ◽  
Valentina Caputo ◽  
Concetta Chiarelli ◽  
Fergus Oliver ◽  
...  

2021 ◽  
Vol 156 ◽  
pp. S62-S63
Author(s):  
Farah El Hadadi ◽  
Line Mezni ◽  
Kaoutar Znati ◽  
Mariame Meziane ◽  
Nadia Ismaili ◽  
...  

1989 ◽  
Vol 21 (5) ◽  
pp. 951-957 ◽  
Author(s):  
Douglas S. Harrington ◽  
Suzanne W. Braddock ◽  
Kathleen S. Blocher ◽  
Dennis D. Weisenburger ◽  
Warren Sanger ◽  
...  

2015 ◽  
Vol 6 (4) ◽  
pp. 95-10
Author(s):  
Dmitriy A. Diakonov ◽  
Nadezhda S. Fedorovskaya ◽  
Alexander S. Luchinin

Primary cutaneous CD4 small/medium T-cell lymphoma is very rare blood disease with usually good prognosis. However similar histology and immunohistochemistry of this pathology with more aggressive T-cells lymphomas, such as mycosis fungoides, make it difficult for pathologist to find the accurate diagnosis. We report about of 40-year-old woman, who came to our clinic with cheek skin lesion.


2021 ◽  
Vol 9 (1) ◽  
pp. 11-16
Author(s):  
Chau M. Bui ◽  
Sumire Kitahara ◽  
Wonwoo Shon ◽  
Tatsiana Pukhalskaya ◽  
Bruce R. Smoller

Cutaneous T-cell lymphomas (CTCLs) are rare tumors with no established markers that can reliably distinguish between benign and malignant lesions. Preferentially Expressed Antigen in Melanoma (PRAME) is a cancer/testis antigen that is found in many solid and hematologic malignancies. PRAME overexpression typically portends a poor prognosis and lower chemotherapeutic response. To date, no studies have established a role for PRAME in CTCL. An analysis was performed on 47 cases definitively diagnosed as CTCL: 25 cases of mycosis fungoides, 2 of Sezary syndrome, 5 of CD30+ lymphoproliferative disorder, 7 of primary cutaneous anaplastic large T-cell lymphoma, 3 of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder, 1 of subcutaneous panniculitis-like T-cell lymphoma, and 4 of angiocentric T-cell lymphoma. PRAME immunohistochemistry was completely negative in all cases. PRAME expression was not found in any CTCL subtypes, suggesting that the pathogenesis of CTCL is not mediated by PRAME. Further study is required to identify biomarkers that might aid in the diagnosis and prognostication of CTCLs.


Sign in / Sign up

Export Citation Format

Share Document